Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glembatumumab vedotin
- Development stage
- Discontinued
- Lead developer
- Celldex Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Glembatumumab vedotin is an antibody-drug conjugate (ADC) composed of a fully human IgG2 monoclonal antibody (CR011) targeting glycoprotein NMB (GPNMB) and linked to monomethyl auristatin E (MMAE), a potent cytotoxic agent. It is designed to selectively kill cancer cells expressing GPNMB. The drug was developed by Celldex Therapeutics Inc for the treatment of various cancers, including breast cancer and melanoma.
- Brand names
- glembatumumab vedotin
- Other names
- CR011CR-011CR 011CR011-VCMMAECR-011-VCMMAECR 011-VCMMAEGlemba
02
Targets
GPNMB (Glycoprotein NMB)
Beyond the preview
Go deeper on glembatumumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glembatumumab vedotin.